GlassScriptPhysician profile
Alison M Rome
NPI 1790998078
$11,883.21
in general payments reported to CMS, 2019-2025
73 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $437 · 2021: $11.97 · 2022: $520 · 2023: $2,343 · 2024: $3,649 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,203 · Long Term Medical Supply Or Device Loan: $781 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,202.93 |
| Long Term Medical Supply Or Device Loan | $781.23 |
| Education | $158.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,461.23 | 2019-2025 | |
| Pfizer INC. | $843.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $738.05 | 2019-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals LP | $694.58 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $681.12 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $606.36 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Astellas Pharma US INC | $432.14 | 2019-2025 | Xtandi, Padcev, Xospata |
| Glaxosmithkline, LLC. | $424.23 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $399.98 | 2019-2025 | Venclexta, Alecensa, Tecentriq |
| Amgen INC. | $398.91 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Genzyme Corporation | $277.10 | 2019-2025 | |
| Celgene Corporation | $269.75 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $235.38 | 2019-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $224.45 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Abbvie INC. | $223.84 | 2023-2025 | Venclexta |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $222.70 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $214.93 | 2019-2025 | Enhertu |
| Pharmaessentia USA Corporation | $213.13 | 2022-2025 | Besremi |
| Incyte Corporation | $174.99 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Eisai INC. | $171.18 | 2019-2025 | |
| Sobi, INC | $170.10 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $159.80 | 2019-2025 | Onivyde |
| Emd Serono, INC. | $132.02 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $130.13 | 2023-2025 | |
| Taiho Oncology, INC. | $128.98 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.87 | 2023-2025 | Alunbrig, Fruzaqla, Iclusig |
| Tesaro, INC. | $112.60 | 2019 | |
| Puma Biotechnology, INC. | $109.61 | 2022-2025 | Nerlynx |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Deciphera Pharmaceuticals INC. | $99.71 | 2023-2025 | Qinlock, Tgct, Romvimza |
| Alexion Pharmaceuticals, INC. | $98.21 | 2023-2025 | Ultomiris |
| Tersera Therapeutics LLC | $88.84 | 2019-2025 | Zoladex |
| Exelixis INC. | $79.98 | 2023-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $68.20 | 2019-2025 | Lynozyfic, Libtayo |
| Immunocore Limited | $65.79 | 2023-2025 | Kimmtrak |
| Stemline Therapeutics INC. | $62.33 | 2025 | Orserdu |
| Karyopharm Therapeutics INC. | $59.70 | 2024-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $58.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.65 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $58.63 | 2024-2025 | |
| Pharming Healthcare, INC. | $58.25 | 2022-2023 | Ruconest |
| Caris Mpi, INC. | $58.06 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $57.23 | 2023-2024 | Fotivda |
| Array Biopharma INC | $55.26 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Seagen INC. | $54.17 | 2020-2023 | Padcev |
| Pharmacosmos Therapeutics INC. | $51.62 | 2023-2025 | Monoferric |
| Beigene USA, INC. | $48.78 | 2024 | Brukinsa |
| Springworks Therapeutics, INC. | $46.37 | 2024 | Ogsiveo |
| Tempus Ai, INC | $43.38 | 2024 | Xt Cdx |
| Corcept Therapeutics | $37.93 | 2025 | Korlym |
| Morphosys, US INC. | $36.47 | 2023 | Monjuvi |
| Boston Scientific Corporation | $34.36 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Kite Pharma, INC. | $31.33 | 2023 | |
| Fennec Pharmaceuticals, INC. | $27.04 | 2024 | Pedmark |
| Recordati_rare_diseases_inc. | $26.33 | 2025 | Enjaymo |
| Sirtex Medical INC | $24.65 | 2024 | Sir-Spheres Microspheres |
| Biocon Biologics INC | $24.38 | 2025 | Ogivri |
| Pharmaand Gmbh | $24.27 | 2025 | Rubraca |
| Tolmar, INC. | $24.27 | 2025 | Rubraca, Eligard |
| Octapharma USA, INC. | $23.10 | 2019 | |
| Myriad Genetic Laboratories, INC. | $21.88 | 2024 | Bracanalysis Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.37 | 2023 | Gilotrif |
| Global Blood Therapeutics, INC. | $19.84 | 2022 | |
| Apo-Pharma USA, INC. | $19.16 | 2019 | |
| Dendreon Pharmaceuticals LLC | $18.94 | 2019 | |
| Blueprint Medicines Corporation | $17.65 | 2020 | |
| Mirati Therapeutics, INC. | $16.44 | 2023 | Krazati |
| Aurobindo Pharma USA, INC. | $15.35 | 2019 | |
| Mylan Institutional INC. | $14.53 | 2020 | |
| Akcea Therapeutics, INC. | $14.49 | 2019 | |
| Tactile Systems Technology INC | $14.12 | 2019 | |
| Iovance Biotherapeutics, INC. | $13.44 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Rome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.